Fujifilm’s Antiviral Becomes First Approved Drug to Treat Coronavirus in China
By HospiMedica International staff writers Posted on 23 Mar 2020 |
Image: Favilavir (Photo courtesy of Fujifilm Toyama Chemical)
Fujifilm Toyama Chemical’s (Tokyo, Japan) flu drug Favilavir, which is currently being promoted with the label, Avigan, has become the first-ever antiviral medicine to be approved for use as a treatment for COVID-19 in China. The National Medical Products Administration of China has approved Favilavir for treating the now-declared pandemic illness after it appeared to be effective in coronavirus patients during clinical studies.
Favilavir, which has proven to be an effective antiviral drug for fighting RNA infections by inhibiting the RNA-dependent RNA polymerase, or RdRp, is mainly used for treating influenza in Japan and China. According to medical authorities in China, Favipiravir had delivered encouraging outcomes in clinical trials of 340 coronavirus-infected patients in Wuhan and Shenzhen. The Ministry of Science and Technology of China has stated that Favilavir was shown to prevent COVID-19 from spreading and further damaging the health of patients in clinical studies. According to reports, the patients in Shenzhen who were administered Favilavir turned negative for the coronavirus after a median of four days after becoming positive, as compared to a median of 11 days for patients who were not treated with the drug. Additionally, X-rays showed improvements in the lung condition of 91% of the patients who were administered Favipiravir, as compared to 62% of patients who were not treated with the drug.
Despite its potential, the US Food and Drug Administration (FDA) has not yet regarded Favilavir as an effective treatment medicine for coronavirus. Nevertheless, doctors in Japan are said to be conducting clinical studies of Favilavir on coronavirus patients having mild to moderate symptoms in the hope of preventing the virus from multiplying in the patients.
Related Links:
Fujifilm Toyama Chemical
Favilavir, which has proven to be an effective antiviral drug for fighting RNA infections by inhibiting the RNA-dependent RNA polymerase, or RdRp, is mainly used for treating influenza in Japan and China. According to medical authorities in China, Favipiravir had delivered encouraging outcomes in clinical trials of 340 coronavirus-infected patients in Wuhan and Shenzhen. The Ministry of Science and Technology of China has stated that Favilavir was shown to prevent COVID-19 from spreading and further damaging the health of patients in clinical studies. According to reports, the patients in Shenzhen who were administered Favilavir turned negative for the coronavirus after a median of four days after becoming positive, as compared to a median of 11 days for patients who were not treated with the drug. Additionally, X-rays showed improvements in the lung condition of 91% of the patients who were administered Favipiravir, as compared to 62% of patients who were not treated with the drug.
Despite its potential, the US Food and Drug Administration (FDA) has not yet regarded Favilavir as an effective treatment medicine for coronavirus. Nevertheless, doctors in Japan are said to be conducting clinical studies of Favilavir on coronavirus patients having mild to moderate symptoms in the hope of preventing the virus from multiplying in the patients.
Related Links:
Fujifilm Toyama Chemical
Latest COVID-19 News
- Low-Cost System Detects SARS-CoV-2 Virus in Hospital Air Using High-Tech Bubbles
- World's First Inhalable COVID-19 Vaccine Approved in China
- COVID-19 Vaccine Patch Fights SARS-CoV-2 Variants Better than Needles
- Blood Viscosity Testing Can Predict Risk of Death in Hospitalized COVID-19 Patients
- ‘Covid Computer’ Uses AI to Detect COVID-19 from Chest CT Scans
- MRI Lung-Imaging Technique Shows Cause of Long-COVID Symptoms
- Chest CT Scans of COVID-19 Patients Could Help Distinguish Between SARS-CoV-2 Variants
- Specialized MRI Detects Lung Abnormalities in Non-Hospitalized Long COVID Patients
- AI Algorithm Identifies Hospitalized Patients at Highest Risk of Dying From COVID-19
- Sweat Sensor Detects Key Biomarkers That Provide Early Warning of COVID-19 and Flu
- Study Assesses Impact of COVID-19 on Ventilation/Perfusion Scintigraphy
- CT Imaging Study Finds Vaccination Reduces Risk of COVID-19 Associated Pulmonary Embolism
- Third Day in Hospital a ‘Tipping Point’ in Severity of COVID-19 Pneumonia
- Longer Interval Between COVID-19 Vaccines Generates Up to Nine Times as Many Antibodies
- AI Model for Monitoring COVID-19 Predicts Mortality Within First 30 Days of Admission
- AI Predicts COVID Prognosis at Near-Expert Level Based Off CT Scans